title: Innovative solutions to novel drug development in mental health.
abstract: There are many new advances in neuroscience and mental health which should lead to a greater understanding of the neurobiological dysfunction in neuropsychiatric disorders and new developments for early, effective treatments. To do this, a biomarker approach combining genetic, neuroimaging, cognitive and other biological measures is needed. The aim of this article is to highlight novel approaches for pharmacological and non-pharmacological treatment development. This article suggests approaches that can be taken in the future including novel mechanisms with preliminary clinical validation to provide a toolbox for mechanistic studies and also examples of translation and back-translation. The review also emphasizes the need for clinician-scientists to be trained in a novel way in order to equip them with the conceptual and experimental techniques required, and emphasizes the need for private-public partnership and pre-competitive knowledge exchange. This should lead the way for important new holistic treatment developments to improve cognition, functional outcome and well-being of people with neuropsychiatric disorders.
authors.affiliation: National Institute of Mental Health, National Institutes of Health, Bethesda, MD, USA.
authors.forename: T R
authors.initials: TR
authors.lastname: Insel
authors.forename: V
authors.initials: V
authors.lastname: Voon
authors.forename: J S
authors.initials: JS
authors.lastname: Nye
authors.forename: V J
authors.initials: VJ
authors.lastname: Brown
authors.forename: B M
authors.initials: BM
authors.lastname: Altevogt
authors.forename: E T
authors.initials: ET
authors.lastname: Bullmore
authors.forename: G M
authors.initials: GM
authors.lastname: Goodwin
authors.forename: R J
authors.initials: RJ
authors.lastname: Howard
authors.forename: D J
authors.initials: DJ
authors.lastname: Kupfer
authors.forename: G
authors.initials: G
authors.lastname: Malloch
authors.forename: H M
authors.initials: HM
authors.lastname: Marston
authors.forename: D J
authors.initials: DJ
authors.lastname: Nutt
authors.forename: T W
authors.initials: TW
authors.lastname: Robbins
authors.forename: S M
authors.initials: SM
authors.lastname: Stahl
authors.forename: M D
authors.initials: MD
authors.lastname: Tricklebank
authors.forename: J H
authors.initials: JH
authors.lastname: Williams
authors.forename: B J
authors.initials: BJ
authors.lastname: Sahakian
mesh_terms: D000818:Animals; D015415:Biomarkers; D001921:Brain / Q000187:drug effects / Q000254:growth & development; D055808:Drug Discovery / Q000379:methods*; D061345:Early Medical Intervention / Q000379:methods; D006801:Humans; D001523:Mental Disorders / Q000188:drug therapy*; D058990:Molecular Targeted Therapy / Q000379:methods; D012109:Research Support as Topic
chemical_list: D015415:Biomarkers
keywords: Back-translation; Biomarkers; Cognitive and psychosocial treatments; Neurobiological mechanisms; Neuropsychiatric disorders; Novel drug development; Pharmacological tool box; Translation
references.citation: Am J Psychiatry. 2010 Jul;167(7):748-51
references.pmid: 20595427
references.citation: Nat Genet. 2011 Sep 18;43(10):977-83
references.pmid: 21926972
references.citation: Mol Psychiatry. 2011 Aug;16(8):826-35, 785
references.pmid: 21502953
references.citation: Cereb Cortex. 2006 Dec;16(12):1679-89
references.pmid: 16436686
references.citation: Am J Psychiatry. 2008 Dec;165(12):1585-93
references.pmid: 18923067
references.citation: Arch Gen Psychiatry. 2005 Jun;62(6):593-602
references.pmid: 15939837
references.citation: Annu Rev Neurosci. 2011;34:289-307
references.pmid: 21692660
references.citation: Arch Gen Psychiatry. 2009 Feb;66(2):128-33
references.pmid: 19188534
references.citation: Harv Rev Psychiatry. 2010 Sep-Oct;18(5):293-303
references.pmid: 20825266
references.citation: Science. 2008 Dec 19;322(5909):1839-42
references.pmid: 19056937
references.citation: J Psychiatr Res. 2012 Jan;46(1):64-71
references.pmid: 21925682
references.citation: Curr Alzheimer Res. 2010 Aug;7(5):374-85
references.pmid: 20043816
references.citation: Biol Psychiatry. 2011 Jan 1;69(1):7-11
references.pmid: 20728875
references.citation: Biol Psychiatry. 2008 Jul 1;64(1):4-10
references.pmid: 18466880
references.citation: Arch Gen Psychiatry. 2006 Aug;63(8):856-64
references.pmid: 16894061
references.citation: Nature. 2011 Feb 10;470(7333):187-97
references.pmid: 21307931
references.citation: Arch Gen Psychiatry. 2010 Aug;67(8):793-802
references.pmid: 20679587
references.citation: Nature. 2010 Jan 28;463(7280):422-3
references.pmid: 20110964
references.citation: Br J Pharmacol. 2011 Jun;163(4):713-21
references.pmid: 21615387
references.citation: Nat Med. 2007 Sep;13(9):1102-7
references.pmid: 17767166
references.citation: Br J Psychiatry. 2009 Apr;194(4):293-5
references.pmid: 19336776
references.citation: Arch Neurol. 1997 Apr;54(4):465-73
references.pmid: 9109749
references.citation: Nature. 2012 Mar 14;483(7389):269
references.pmid: 22422245
references.citation: Lancet. 2007 Sep 8;370(9590):807-8
references.pmid: 17826153
references.citation: Nature. 2011 Jul 06;475(7354):27-30
references.pmid: 21734685
references.citation: Proc Natl Acad Sci U S A. 2007 Dec 4;104(49):19649-54
references.pmid: 18024590
references.citation: Nat Genet. 2011 Sep 18;43(10):969-76
references.pmid: 21926974
references.citation: Acad Psychiatry. 2010 Mar-Apr;34(2):87-9
references.pmid: 20224010
references.citation: Lancet. 2010 May 29;375(9729):1854-5
references.pmid: 20511002
references.citation: J Med Chem. 2010 Jun 24;53(12):4603-14
references.pmid: 20491477
references.citation: Curr Opin Pharmacol. 2011 Oct;11(5):521-7
references.pmid: 21723195
references.citation: J Neurosci. 1997 Dec 1;17(23):9285-97
references.pmid: 9364074
references.citation: Neuropsychopharmacology. 2004 Jul;29(7):1363-73
references.pmid: 15085092
references.citation: Lancet. 1991 Jul 6;338(8758):50-1
references.pmid: 1676097
references.citation: Biol Psychiatry. 2010 Mar 1;67(5):432-8
references.pmid: 20074703
references.citation: Science. 2010 Jul 30;329(5991):502-4
references.pmid: 20671165
references.citation: Arch Gen Psychiatry. 2004 Nov;61(11):1136-44
references.pmid: 15520361
references.citation: Trends Neurosci. 2002 Jul;25(7):340-3
references.pmid: 12079756
references.citation: J Clin Psychopharmacol. 2008 Dec;28(6):631-7
references.pmid: 19011431
references.citation: Eur Neuropsychopharmacol. 2011 Jul;21(7):495-9
references.pmid: 21684455
references.citation: Nature. 2011 May 12;473(7346):221-5
references.pmid: 21490598
references.citation: Psychopharmacology (Berl). 2009 Jan;202(1-3):287-93
references.pmid: 18392753
references.citation: Nature. 2008 Oct 23;455(7216):1057-60
references.pmid: 18948946
references.citation: J Abnorm Psychol. 2010 Nov;119(4):631-9
references.pmid: 20939653
references.citation: Nat Neurosci. 2007 Sep;10(9):1116-24
references.pmid: 17726478
references.citation: Nature. 1997 Apr 24;386(6627):824-7
references.pmid: 9126739